Observations in lung cancer over multiple decades: An analysis of outcomes and cost at a single high-volume institution

European Journal of Cardio-thoracic Surgery

Volumn 46, Issue 2, 2014, Pages 254-261

  Lanuti, Michael ^a   Hong, Hyo Jung ^a   Ali, Shihab ^a   Stock, Cameron ^a   Temel, Jennifer ^a   Mathisen, Douglas ^a   Michaelson, James S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cost; Lung cancer; Survival analysis; Time trends

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL DATA REPOSITORY; CLINICAL OBSERVATION; CONTROLLED STUDY; COST OF ILLNESS; DATA EXTRACTION; DISEASE FREE SURVIVAL; FEMALE; HEALTH CARE COST; HIGH VOLUME HOSPITAL; HOSPITAL BILLING; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SOCIAL SECURITY; SURVIVAL TIME; TREATMENT DURATION; ECONOMICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84905506474     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezt611     Document Type: Article

References (16)

1. Globocan, Section of Cancer Information, 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?Uno=900. (June 2013, date last accessed).
2. Riquet M, Berna P, Fabre E, Arame A, Dujon A, Foucault C et al. Evolving characteristic of lung cancer: a surgical appraisal. Eur J Cardiothorac Surg 2012;41:1019-24.
3. Hanagiri T, Baba T, So T, Yasuada M, Sugaya M, Ono K et al. Time trends of surgical outcome in patients with NSCLC. J Thorac Oncol 2010;5:825-9.
4. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Sheperd FA, Stephens RJ et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group. J Clin Oncol 2008;26:3552-9.
5. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
6. National Lung Cancer Screening Trial Research Team. Reduced lungcancer mortality with low dose CT screening. N Engl J Med 2011;365: 395-409.
7. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S.
8. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. 7th edition Lung Cancer Staging. American Joint Committee on Cancer. In: Cancer Staging Handbook. Chicago: Springer, 2010, 299-323.
10. US National Institute of Health. Surveillance Epidemiology and End Results. National Cancer Institute, 2003-2009 http://seer.cancer.gov/faststats/index (11 June 2013, date last accessed).
11. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010;25:1113-21.
12. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-96.
13. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer; geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31.
14. WHO report on the global tobacco epidemic; the MPOWER package. World Health Organization, Geneva, Switzerland, 2008.
15. Strand TE, Bartnes K, Rostad HH. National trends in lung cancer surgery. Eur J Cardiothorac Surg 2012;42:355-8.
16. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:1-12.